| 37758193 | A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. | Neuro Oncol | 2024 |
| 37758193 | A combinatory vaccine with IMA950 plus varlilumab promotes effector memory T-cell differentiation in the peripheral blood of patients with low-grade gliomas. | Neuro Oncol | 2024 |
| 36599113 | Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. | J Clin Oncol | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 37899778 | Quantitative analysis of <i>MGMT</i> promoter methylation in glioblastoma suggests nonlinear prognostic effect. | Neurooncol Adv | 2023 |
| 38079020 | "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. | Acta Neuropathol | 2023 |
| 37611371 | Multi-parametric hyperpolarized <sup>13</sup>C/<sup>1</sup>H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomas. | Neuroimage Clin | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 36599113 | Interactive Effects of Molecular, Therapeutic, and Patient Factors on Outcome of Diffuse Low-Grade Glioma. | J Clin Oncol | 2023 |
| 37503127 | NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy. | bioRxiv | 2023 |
| 38079020 | "De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockade. | Acta Neuropathol | 2023 |
| 37899778 | Quantitative analysis of <i>MGMT</i> promoter methylation in glioblastoma suggests nonlinear prognostic effect. | Neurooncol Adv | 2023 |
| 37944590 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Nat Med | 2023 |
| 37611371 | Multi-parametric hyperpolarized <sup>13</sup>C/<sup>1</sup>H imaging reveals Warburg-related metabolic dysfunction and associated regional heterogeneity in high-grade human gliomas. | Neuroimage Clin | 2023 |
| 37503127 | NOTCH3 drives meningioma tumorigenesis and resistance to radiotherapy. | bioRxiv | 2023 |
| 36993741 | Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses. | Res Sq | 2023 |
| 34882581 | Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. | J Clin Invest | 2022 |
| 35911636 | Embedding palliative care in a neuro-oncology clinic at an academic medical center: Our structure, experience, and lessons learned. | Neurooncol Adv | 2022 |
| 35395677 | Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. | Neuro Oncol | 2022 |
| 36239858 | Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). | Discov Oncol | 2022 |
| 35703914 | Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. | J Neuropathol Exp Neurol | 2022 |
| 35759011 | Intratumor and informatic heterogeneity influence meningioma molecular classification. | Acta Neuropathol | 2022 |
| 36007439 | Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-<sup>13</sup>C]pyruvate MRI data from patients with glioma. | Neuroimage Clin | 2022 |
| 35945463 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Acta Neuropathol | 2022 |
| 35534562 | Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. | Nat Genet | 2022 |
| 36479058 | Longitudinal MR spectroscopy to detect progression in patients with lower-grade glioma in the surveillance phase. | Neurooncol Adv | 2022 |
| 34982879 | Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. | Neurosurgery | 2022 |
| 34882581 | Randomized trial of neoadjuvant vaccination with tumor-cell lysate induces T cell response in low-grade gliomas. | J Clin Invest | 2022 |
| 35703914 | Targeted Next-Generation Sequencing Reveals Divergent Clonal Evolution in Components of Composite Pleomorphic Xanthoastrocytoma-Ganglioglioma. | J Neuropathol Exp Neurol | 2022 |
| 35534562 | Meningioma DNA methylation groups identify biological drivers and therapeutic vulnerabilities. | Nat Genet | 2022 |
| 35759011 | Intratumor and informatic heterogeneity influence meningioma molecular classification. | Acta Neuropathol | 2022 |
| 35395677 | Prospective genomically guided identification of "early/evolving" and "undersampled" IDH-wildtype glioblastoma leads to improved clinical outcomes. | Neuro Oncol | 2022 |
| 36479058 | Longitudinal MR spectroscopy to detect progression in patients with lower-grade glioma in the surveillance phase. | Neurooncol Adv | 2022 |
| 35911636 | Embedding palliative care in a neuro-oncology clinic at an academic medical center: Our structure, experience, and lessons learned. | Neurooncol Adv | 2022 |
| 36239858 | Tumor Treating Fields (TTFields) therapy vs physicians' choice standard-of-care treatment in patients with recurrent glioblastoma: a post-approval registry study (EF-19). | Discov Oncol | 2022 |
| 36007439 | Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized [1-<sup>13</sup>C]pyruvate MRI data from patients with glioma. | Neuroimage Clin | 2022 |
| 35945463 | Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1. | Acta Neuropathol | 2022 |
| 34982879 | Association of Neurological Impairment on the Relative Benefit of Maximal Extent of Resection in Chemoradiation-Treated Newly Diagnosed Isocitrate Dehydrogenase Wild-Type Glioblastoma. | Neurosurgery | 2022 |
| 33398537 | Correction to: Global postâ¿¿marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with highâ¿¿grade glioma in clinical practice. | J Neurooncol | 2021 |
| 34125374 | A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. | J Neurooncol | 2021 |
| 33887769 | Letter: Patterns of Intermediate- and High-Risk Meningioma Recurrence After Treatment With Postoperative External Beam Radiotherapy. | Neurosurgery | 2021 |
| 33823014 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. | Neuro Oncol | 2021 |
| 33398537 | Correction to: Global postâ¿¿marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with highâ¿¿grade glioma in clinical practice. | J Neurooncol | 2021 |
| 34519829 | Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. | Neuro Oncol | 2021 |
| 33823014 | Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. | Neuro Oncol | 2021 |
| 33887769 | Letter: Patterns of Intermediate- and High-Risk Meningioma Recurrence After Treatment With Postoperative External Beam Radiotherapy. | Neurosurgery | 2021 |
| 34519829 | Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. | Neuro Oncol | 2021 |
| 34125374 | A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. | J Neurooncol | 2021 |
| 31609499 | Myxoid glioneuronal tumor, PDGFRA p.K385-mutant: clinical, radiologic, and histopathologic features. | Brain Pathol | 2020 |
| 32027343 | Association of Maximal Extent of Resection of Contrast-Enhanced and Non-Contrast-Enhanced Tumor With Survival Within Molecular Subgroups of Patients With Newly Diagnosed Glioblastoma. | JAMA Oncol | 2020 |